Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Intrathecal Resiniferatoxin

Phase 1Small molecule

NNational Institute of Dental and Craniofacial Research (NIDCR)

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Pain

NCT00804154

Clinical

Trials by Indication[1]

Pain1 trial

A Phase I Study of the Intrathecal Administration of Resiniferatoxin for Treating Severe Refractory Pain Associated With Advanced Cancer

Recruiting·NNational Institute of Dental and Craniofacial Research (NIDCR)·Phase 1·NCT00804154·45 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Intrathecal Resiniferatoxin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intrathecal Resiniferatoxin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intrathecal Resiniferatoxin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Institute of Dental and Craniofacial Research (NIDCR) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNational Institute of Dental and Craniofacial Research (NIDCR)

Related News